Work

CAR T Cells for Acute Myeloid Leukemia: The LeY of the Land

Year: 2013

Type: article

Abstract: Recent studies of CD19-directed chimeric antigen receptor (CAR)-expressing T cells have shown dramatic results in the treatment of acute lymphoblastic leukemia as well as activity in B-cell lymphoma.1,2,3 These highly publicized studies have led to the hope that CAR T cells can be used to treat other hematological malignancies and solid tumors as well. The article by Ritchie et al. in this issue4 shows how the approach can be adapted for the treatment of patients with acute myeloid leukemia (AML) and illustrates that significant obstacles remain before this biological therapy will become a mainstay of treatment.

Source: Molecular Therapy

DOI: 10.1038/mt.2013.234

Author: Malcolm K Brenner

Institutions: Houston Methodist, Baylor College of Medicine, Texas Children's Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,500